In Brief: DynaGen
DynaGen: Acquires Alpharma subsidiary Able Labs, Cambridge, Mass.-based firm announces Aug. 12. DynaGen is paying $550,000 in cash for the business; Able had $2.5 mil. in 1995 revenues and operated at a loss. DynaGen will acquire rights to 10 approved tablet and suppository ANDA products, a 46,000 sq. ft. manufacturing facility in South Plainfield, N.J. and 45 employees. DynaGen plans to establish a multi-source and specialty pharmaceutical division. It is developing NicErase sublingual lobeline for smoking cessation and anticipates the Able acquisition would provide manufacturing for the product. DynaGen will have $9 mil. in cash after the acquisition...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth